Background: Posterior fossa (PF) ependymomas (EPNs) in infants less than 1 year of age (iEPN-PF) have a poorer clinical outcome than EPNs in older children. While radiation therapy is the standard of care for the latter, it is withheld in infants to avoid neurotoxicity to immature brain. It is unknown whether the adverse outcome in iEPN-PFs is due to treatment differences or aggressive biology. We examined this question using molecular profiling.
INTRODUCTION
Ependymomas (EPNs) are the third most common brain tumor in the pediatric population, with two-thirds located in the posterior fossa (PF) and one-third in the supratentorial (ST) compartment. 1 Abbreviations: AT/RT, atypical teratoid/rhabdoid tumor; CDK4/6, cyclin-dependent kinase 4/6; CDKN2A, cyclin-dependent kinase inhibitor 2A; CNA, copy number alteration; COMIRB, Colorado Multiple Institutional Review Board; DAVID, Database for Annotation, Visualization, and Integrated Discovery; EPN, ependymoma; FDA, Food and Drug Administration; FDR, false discovery rate; GEO, Gene Expression Omnibus; GFAP, glial fibrillary acidic protein; GSEA, Gene Set Enrichment Analysis; iEPN-PF, infant posterior fossa ependymoma; IHC, immunohistochemistry; LOH, loss of heterozygosity; NES, normalized enrichment score; NMF, nonnegative matrix factorization; OS, overall survival; PF, posterior fossa; PFA, PF subgroup A; PFB, PF subgroup B; PFS, progression-free survival; RB, retinoblastoma; ST, supratentorial; WHO, World Health Organization EPNs are histologically graded as either World Health Organization (WHO) grade II or III (anaplastic) tumors. 2 However, the histological distinction between grades II and III can be difficult. 3, 4 Recent large-scale genomic, transcriptomic, and methylation array profiling studies have elucidated significant differences in EPNs from different anatomic sites with respect to the molecular features and prognosis, despite histopathological similarities. [5] [6] [7] [8] [9] A recent multiinstitutional and multivariate analysis by Pajtler et al. of 500 EPNs resulted in a proposed molecular classification of EPNs into nine distinct molecular subgroups. 9 Two subgroups were identified within the PF: PF subgroup A (PFA) and PF subgroup B (PFB). 7, 8 Aside from the molecular subgrouping, copy number gains of the long arm of chromosome 1 (1q) and extent of surgical resection were the only remaining independent prognostic factors. 9 PFA tumors harbored the highest frequencies of gain of 1q, which significantly influenced the overall survival (OS) within this subgroup. Interestingly, despite an increased frequency of gains of 1q in ST RELAfusion EPNs, 1q gain did not adversely impact OS as significantly as it did in the PFA. 9 However, homozygous loss of the cyclindependent kinase inhibitor 2A (CDKN2A) locus (on chromosome 9p21) has consistently been shown to be of poor prognostic significance and has been reported to be more frequent within ST RELA-fusion EPNs. 1, 5, 6, 9 EPNs occurring within the infant period (age <1 year) are associated with a particularly poor survival rate of only 42-55% at 5 years after diagnosis, despite the fact that infants typically handle surgery well. 10 While postoperative radiation is standard-of-care therapy for EPNs in older children, in infants radiation is withheld until 12 months of age to avoid toxicity to the developing brain. The poor survival in infant EPN has been attributed to withholding radiotherapy. However, few previous studies have focused efforts on studying any potential biological differences in infant EPNs due to their relative infrequency.
Indeed, in the recent study by Pajtler et al., only 12 of 168 EPNs (7.1%) for which age was reported occurred in infants less than 1 year of age. 9 The subset of infant EPNs confined to the posterior fossa (iEPN-PF) was even smaller (n = 6). 9 The current study compares iEPN-PFs with PF EPNs in older children of similar PF group and histological grade. Our cohort of six iEPNPFs was examined for transcriptomic characteristics and the known prognostic genetic markers,1q gain and p16 loss. These features were compared to EPN in older children and correlated with clinical outcome. Elucidation of biological characteristics unique to iEPN-PF may be a critical step to the development of effective therapies for this particularly vulnerable infant subgroup, which has not been specifically addressed in other studies. 9 
MATERIALS AND METHODS

Patient cohort
All studies were conducted in compliance with local and federal research protection guidelines and institutional review board regula- 
Routine histology and immunohistochemistry
Tissues were fixed in 10% buffered formalin and cut at 5 m. Immunohistochemistry (IHC) was performed on formalin-fixed, paraffinembedded tumor tissue sections. IHCs that had originally been utilized for diagnostic purposes at the time of initial assessment varied, but in most cases included glial fibrillary acidic protein (GFAP; Dako Corporation, Carpinteria, CA, polyclonal, 1:2,500, no antigen retrieval), MIB-1 (Dako Corporation; monoclonal, 1:400 dilution, antigen retrieval), and p16 (Ventana, monoclonal, predilute, antigen retrieval). MIB-1 counts were performed manually based on 5,000 cells. Scoring for p16 was conducted using previously published methods (strong >50% of cells positive, moderate 10-50% of cells, weak <10%, or negative). 11
Transcriptomic analysis
EPN transcriptomic study cohort data were obtained from a prior study of EPN molecular subgroups conducted by our laboratory. 12 These gene expression microarray data are available through the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database 13 (GEO Series accession number GSE66354; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE66354). All patient samples were obtained with consent (COMIRB 95-500) and processed identically using the Human Genome U133plus2 Array (Affymetrix) platform as described previously. 12 Clustering analysis was done using transcriptomic data from 50 primary pediatric EPN patients for whom samples were available at our institution; this data set included the six iEPN-PFs. Within the expanded pediatric EPN data set, nine tumors had been ST and 41 had been infratentorial. These 50 samples were assigned to consensus molecular subgroups using nonnegative matrix factorization (NMF) of transcriptomic profiles available through the Broad Institute Gene Pattern platform. Ontology tools Database for Annotation, Visualization, and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov) and Gene Set Enrichment Analysis (GSEA) were used to assess enrichment of gene sets. Gene sets found to be enriched in our cohort of iEPN-PF were validated in an independently published EPN data set from the German Cancer Research Center, Heidelberg, Germany (GSE64415). This validation cohort contained 12 iEPNs and 156 noninfant, older pediatric EPNs for which age was reported.
FISH
FISH was conducted to evaluate the copy number status of p16 (CDKN2A, 9p21) and 1q25. Briefly, dual-color FISH probe sets, manufactured by Vysis (Abbott Laboratories Inc., Des Plaines, IL), were used for loss of heterozygosity (LOH) studies of chromosome 1q25 (Spectrum Green) and 9p21 (Spectrum Orange) with nine centromere as internal control. DNA copy number alterations (CNAs) were further examined in a large independent cohort of molecularly classified EPN that was recently published by Pajtler et al. 9 CNAs, identified by examination of the combined intensity values of Illumina 450K methylation Chemo, protocol chemotherapy regimen; DOD, died of disease; GTR, gross total resection; LOH, loss of heterozygosity; STR, subtotal resection; XRT, radiation therapy; "-", used when data are not available.
probes, were matched with patient age and molecular subtype for comparative analyses.
Survival analysis
Kaplan-Meier plots and log-rank (Mantel-Cox) tests were used to estimate survival probability. OS was calculated from the date of initial diagnosis to death from any cause. Patients who had not had an event (death or progression) at the time of analysis were censored.
Statistical analysis
Statistical analyses were performed using Prism (GraphPad) and Excel (Microsoft) software. For all tests, significance was defined as P-value < 0.05.
RESULTS
iEPN-PF: Patient characteristics and pathologic features
Six EPN were identified in patients <1 year of age (four male, two female) ( Table 1 ). All iEPN-PF cases showed similar histologic features including relatively monomorphic cells with round to oval nuclei, speckled chromatin, perivascular pseudorosettes with GFAP-positive fibrillary processes oriented radially around vessels, and often showed hyalinization of tumor vessels. These tumors showed no histological dissimilarity to anaplastic PF EPN in noninfants in our comparison cohort. All six iEPN-PFs met histologic criteria for anaplastic WHO grade III, with mitotic counts ≥5 mitoses per 10 high power (40×) microscopic fields (Figs. 1A-1D ). 
All PF iEPN-PFs cluster with EPN PFA
Unbiased clustering analysis (NMF) was performed on transcriptomic profiles from primary tumor samples of iEPN-PFs (n = 6) and compared with 44 noninfant pediatric EPNs in our larger EPN tumor bank (all deposited in GEO: series accession number GSE66354). NMF analysis identified three molecular subgroups-ST, PFA, and PFB as described previously. 12 All six iEPN-PFs were clustered within the PFA (Supplementary Fig. S1 ).
iEPN-PF harbor unique transcriptomic signatures compared to subgroup and grade-matched EPN in older patients
Based on our observation that all iEPN-PF were in PFA, we first nar- Transcriptomic analysis compared all six anaplastic iEPN-PF to noninfant anaplastic EPN PFA (n = 7). These groups were subjected to a more-thorough GSEA ontological analysis to identify differential enrichment of well-defined biological states and processes using Molecular Signatures Database Hallmark gene sets (n = 50). Even when adjusted to compare only anaplastic EPN PFA, the ontologies associated with iEPN-PF were, similar to the preliminary analysis, largely related to mitosis and cell cycle (Table 2) . Notably, most enriched gene sets were Hallmark_E2F_targets (normalized enrichment score [NES] = 2.14) and Hallmark_G2M_checkpoint (NES = 2.20)
(both FDR q < 0.0001) ( Figs. 2A and 2B ).
Gene sets enriched in our cohort of iEPN-PF were validated in an independent data set (GSE64415). As this data set contained infant EPN from both PF and ST sites, we compared iEPNs (n = 12; six PF, six ST) to noninfant EPN (n = 156; median 12 years, 109 PF and spine, 47
ST) from all anatomic locations. 9 GSEA analysis of the German cohort validated our finding that Hallmark_E2F_target (NES = 2.27) and Hallmark_G2M_checkpoint (NES = 2.08) gene sets were the most enriched gene sets in infant EPN (FDR q < 0.0001) ( Table 2 ).
The upregulation of mitotic activity in iEPN-PF suggested by the enrichment of numerous mitosis-associated gene sets was confirmed by immunohistochemical MIB-1 labeling indices, showing significantly higher (P = 0.01) rates in iEPN-PF (mean = 53%) than the noninfant PFA EPNs (mean = 34%) ( Table 1) . that was not significantly associated with site of disease. 14 Given this discrepancy, we suspect that, unlike larger changes such as 1q gain, potentially smaller genetic alterations of p16 cannot be easily assessed by CNA analysis of Illumina 450K methylome data.
Patient demographics and clinical outcome
IHC for p16 protein expression was therefore performed to further identify possible differences in iEPN-PF versus noninfant anaplastic PFA EPN (Figs. 1 E and 1F ). As detailed in Table 1 , the IHC expression that, similar to iEPN-PF, occurs predominantly in children less than 3 years of age. p16 was shown to be silenced in AT/RT via a process that involves chromatin methylation and remodeling. 15, 16 Epigenetic silencing may also underlie loss of p16 protein expression in a portion of cells in noninfant EPN that showed moderate to strong expression ( Fig. 1F) , despite a lack of apparent genetic alterations in these samples.
DISCUSSION
Despite advances in neurosurgery and postoperative adjuvant therapy, prognosis remains relatively poor for pediatric EPNs, with 5-year survival rates ranging from 39 to 64%, and 5-year progression-free survival (PFS) from 23 to 45%. 17 The clinical behavior of EPNs is highly variable, with late relapses occurring up to 15 years after initial treatment and local recurrences in 50% of patients even with gross total resection. 18 Up to 40% of patients have incurable tumors. 19, 20 iEPN-PFs have a particularly poor prognosis. 17, [19] [20] [21] The aim of this study was to further explore the biology of iEPN-PFs, all of which in our study grouped within PFA were WHO grade III tumors. This PFA subgrouping was anticipated by Pajtler et al. who showed that PFA EPNs were almost exclusively found in young children and resulted in a very poor prognosis compared to other EPN molecular subgroups. 9 Indeed, PFA EPNs paralleled the ST RELA-fusion subgroup in terms of similar poor OS and event-free survival/PFS rates. 9 Our study demonstrates that iEPN-PFs potentially make a major contribution to the adverse OS and PFS within the PFA, as the OS data approach near-equivalence for the PFA and PFB when the iEPN-PFs are separated out.
Overexpression of cell cycle and mitosis-related genes and gene sets for PF tumors and the PFA EPN has been previously demonstrated. 7, 9, 22 However, the current study further shows that these gene sets appear primarily overexpressed within the PFA iEPN-PF cohort when compared to the noninfant pediatric PFA EPN cohort. Increased MIB-1 (Ki-67) is known to be associated with worse outcomes for EPN and is particularly associated with PF tumors. [23] [24] [25] We have demonstrated overexpression of mitosis and cell cycle related gene sets within the PFA iEPN-PF group versus the noninfant PFA EPN group, as well as a statistically significant higher average MIB-1 rate than the noninfant pediatric group, despite identical WHO grade III (P = 0.01).
Further genomic, transcriptomic, and immunohistochemical analyses of iEPN-PF identified a potential mechanism underlying the elevated mitotic activity in these tumors. Loss of p16 was shown to be more frequent in iEPN-PFs, whereas the high-risk genetic feature of 1q gain was absent. Loss of p16 is known to be associated with a poor outcome in patients with ST RELA-fusion tumors and is infrequently observed within the other subgroups of EPNs. 5, 9, 24 Copy number gains of 1q were identified to be the most common copy number variation within primary and recurrent EPNs and, in some studies, have been shown to serve as an independent marker for tumor progression. 1, 26 Additionally This negative impact may surpass any gain of 1q as an adverse prognostic factor, at least in iEPN-PFs.
The finding of p16 loss additionally represents a potential therapeutic vulnerability in iEPN-PF, as tumors harboring p16 loss are potentially sensitive to CDK4/6 inhibitors. 28, 29 Deregulation of the p16-CDK4/6-pRB-E2F pathway has been described in other brain tumors, notably adult glioblastoma where therapeutic targeting of this pathway with CDK4/6 inhibitor palbociclib is being explored preclinically and clinically. 30, 31 Of relevance to potential treatment of iEPN-PF, palbociclib was well tolerated and showed stabilization of tumor growth in pediatric intracranial growing teratoma syndrome. 32
To our knowledge, however, no trials are ongoing for the use of palbociclib in EPNs of any type.
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